Table of Contents

Table 00: Comments

1 The data was extracted from the GARFIELD-AF registry database on 28 JUL 2016

2 The data includes retrospective patients in cohort 1 and prospective patients in cohort 1, 2, 3, 4 and 5

3 The variable ‘Congestive heart failure’ was split into ‘History of CHF’ and ‘Current CHF’ in cohorts 3, 4 and 5.History of and/or current CHF were used to identify CHF in cohort 3, 4 and 5 patients (Table 6)

4 The variable ‘Coronary artery disease’ was split into ‘History of CAD’ and ‘Current CAD’ in cohorts 3, 4 and 5.History of and/or current CAD were used to identify CAD in cohort 3, 4 and 5 patients (Table 6)

5 The variable ‘Other thromboembolism’ is not recorded for patients in cohort 3, 4 and 5

6 The option ‘None’ was added in the CRF for the ‘Chronic renal disease’ field in cohort 3, 4 and 5.The percentages for the variable 'Moderate to severe CKD' are estimated assuming that patients with 'unknown' stage of CKD are without 'Moderate to severe CKD' (Table 6)

7 Table 7 describes the baseline treatment for stroke prophylaxis. For each treatment group identifier options are mutually exclusive.The option 'unknown' includes combination of treatments

8 Table 8 shows the baseline treatment for stroke prophylaxis with non mutually exclusive groups

9 Table 12 shows INR values and TTR for patients treated with VKA±AP at baseline. INR readings during the first year of follow-up were included in the analysis. Values less than 0.8 or greater than 20 were removed since these values may not be plausible. Patients on VKA±AP at enrolment but with fewer than three readings during the follow-up were excluded from the analysis. Patient-level TTR was estimated by linear interpolation according to Rosendaal et al (1993), using 2.0-3.0 as the target INR range. TTR was estimated using INR readings until discontinuation or interruption of VKA or the end of follow-up. In addition, TTR was estimated between two consecutive INR readings only if the interval did not exceed 90 days.

10 Tables 13 and 14 describe events during the first year of follow-up for patients in cohorts 1-4. Only the first occurrence of each event was taken into account.

11 Table 13 Congestive heart failure during the follow-up includes new congestive heart failure or worsening of pre-existing congestive heart failure.

Table 01: Study population and enrolment information
Full Analysis Dataset : POLAND

Number of prospective patients (C1+C2+C3+C4+C5)	2400
Number of enrolling sites	46
Number of enrolling countries	1
Enrolment period	15JUL2010 - 22JUL2016
Duration of enrolment (months)	72.3

Table 02: Patients by region, country, and cohort
Full Analysis Dataset : POLAND

Region	Country	Cohort 1 Retrospective patients (N=411)	Cohort 1 Prospective patients (N=499)	Cohort 2 (N=606)	Cohort 3 (N=506)	Cohort 4 (N=423)	Cohort 5 (N=366)	Total Prospective patients Cohorts 1 to 5 (N=2400)	Total Prospective patients Cohorts 1 to 4 (N=2034)
Europe	Poland	411	499	606	506	423	366	2400	2034

Table 03 : Demographic Characteristics
Full Analysis Dataset : POLAND

Variable	Statistics	Cohort 1 Retrospective patients (N=411) (n %)	Cohort 1 Prospective patients (N=499) (n %)	Cohort 2 (N=606) (n %)	Cohort 3 (N=506) (n %)	Cohort 4 (N=423) (n %)	Cohort 5 (N=366) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2400)	Total Prospective patients Cohorts 1 to 4 (N=2034)
Sex, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	506 (0)	423 (0)	366 (0)	2400 (0)	2034 (0)
	Male	213 (51.8)	268 (53.7)	340 (56.1)	270 (53.4)	235 (55.6)	217 (59.3)	1330 (55.4)	1113 (54.7)
	Female	198 (48.2)	231 (46.3)	266 (43.9)	236 (46.6)	188 (44.4)	149 (40.7)	1070 (44.6)	921 (45.3)
Age at Diagnosis (Years)	n (missing)	410 (1)	499 (0)	606 (0)	506 (0)	423 (0)	366 (0)	2400 (0)	2034 (0)
	Mean (SD)	65.4 (10.5)	68.3 (10.8)	67.3 (11.0)	67.5 (11.2)	67.4 (11.3)	68.1 (10.7)	67.7 (11.0)	67.6 (11.1)
	Median (IQR)	65.0 (58.0 to 74.0)	69.0 (61.0 to 77.0)	67.0 (60.0 to 76.0)	68.0 (60.0 to 76.0)	68.0 (60.0 to 76.0)	68.0 (62.0 to 75.0)	68.0 (61.0 to 76.0)	68.0 (60.0 to 76.0)
	Min to Max	30 to 91	33 to 90	26 to 96	25 to 92	30 to 90	32 to 95	25 to 96	25 to 96
Age Group, n(%)	n (missing)	410 (1)	499 (0)	606 (0)	506 (0)	423 (0)	366 (0)	2400 (0)	2034 (0)
	<65	197 (48.0)	189 (37.9)	252 (41.6)	193 (38.1)	167 (39.5)	126 (34.4)	927 (38.6)	801 (39.4)
	65-74	121 (29.5)	155 (31.1)	170 (28.1)	160 (31.6)	135 (31.9)	141 (38.5)	761 (31.7)	620 (30.5)
	>=75	92 (22.4)	155 (31.1)	184 (30.4)	153 (30.2)	121 (28.6)	99 (27.0)	712 (29.7)	613 (30.1)
Time since AF Diagnosis (Weeks)	n (missing)	410 (1)	452 (47)	521 (85)	437 (69)	377 (46)	327 (39)	2114 (286)	1787 (247)
	Mean (SD)	58.34 (23.75)	1.73 (1.74)	1.52 (1.46)	1.58 (1.54)	1.54 (1.55)	1.63 (1.50)	1.60 (1.56)	1.59 (1.57)
	Median (IQR)	54.30 (36.80 to 78.10)	1.00 (0.50 to 2.80)	1.00 (0.50 to 2.10)	1.00 (0.40 to 2.20)	1.00 (0.40 to 2.10)	1.10 (0.50 to 2.20)	1.00 (0.50 to 2.20)	1.00 (0.50 to 2.20)
	Min to Max	26.1 to 104.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0
Race, n(%)	n (missing)	408 (0)	494 (0)	605 (0)	503 (0)	423 (0)	366 (0)	2391 (0)	2025 (0)
	Caucasian	406 (99.5)	494 (100.0)	593 (98.0)	492 (97.8)	421 (99.5)	364 (99.5)	2364 (98.9)	2000 (98.8)
	Hispanic/Latino	1 (0.2)	-	-	1 (0.2)	-	-	1 (0.0)	1 (0.0)
	Mixed/Other	1 (0.2)	-	12 (2.0)	10 (2.0)	2 (0.5)	2 (0.5)	26 (1.1)	24 (1.2)
	Unknown	3	5	1	3	-	-	9	9

Table 03 : Demographic Characteristics
Full Analysis Dataset : POLAND

Variable	Statistics	Cohort 1 Retrospective patients (N=411) (n %)	Cohort 1 Prospective patients (N=499) (n %)	Cohort 2 (N=606) (n %)	Cohort 3 (N=506) (n %)	Cohort 4 (N=423) (n %)	Cohort 5 (N=366) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2400)	Total Prospective patients Cohorts 1 to 4 (N=2034)
Region, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	506 (0)	423 (0)	366 (0)	2400 (0)	2034 (0)
	Europe	411 (100.0)	499 (100.0)	606 (100.0)	506 (100.0)	423 (100.0)	366 (100.0)	2400 (100.0)	2034 (100.0)

Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : POLAND

Variable	Statistics	Cohort 1 Retrospective patients (N=411) (n %)	Cohort 1 Prospective patients (N=499) (n %)	Cohort 2 (N=606) (n %)	Cohort 3 (N=506) (n %)	Cohort 4 (N=423) (n %)	Cohort 5 (N=366) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2400)	Total Prospective patients Cohorts 1 to 4 (N=2034)
Care Setting Speciality at Diagnosis, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	506 (0)	423 (0)	366 (0)	2400 (0)	2034 (0)
	Internal Medicine	104 (25.3)	137 (27.5)	169 (27.9)	99 (19.6)	77 (18.2)	67 (18.3)	549 (22.9)	482 (23.7)
	Cardiology	243 (59.1)	323 (64.7)	370 (61.1)	349 (69.0)	311 (73.5)	273 (74.6)	1626 (67.8)	1353 (66.5)
	Neurology	7 (1.7)	1 (0.2)	6 (1.0)	10 (2.0)	3 (0.7)	-	20 (0.8)	20 (1.0)
	Geriatrics	-	-	3 (0.5)	-	3 (0.7)	-	6 (0.3)	6 (0.3)
	Primary Care/General Practice	57 (13.9)	38 (7.6)	58 (9.6)	48 (9.5)	29 (6.9)	26 (7.1)	199 (8.3)	173 (8.5)
Care Setting Location at Diagnosis, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	506 (0)	423 (0)	366 (0)	2400 (0)	2034 (0)
	Hospital	281 (68.4)	404 (81.0)	450 (74.3)	337 (66.6)	295 (69.7)	257 (70.2)	1743 (72.6)	1486 (73.1)
	Office	109 (26.5)	65 (13.0)	103 (17.0)	122 (24.1)	90 (21.3)	65 (17.8)	445 (18.5)	380 (18.7)
	Emergency room	21 (5.1)	30 (6.0)	53 (8.7)	47 (9.3)	38 (9.0)	44 (12.0)	212 (8.8)	168 (8.3)
Type of AF Diagnosed, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	506 (0)	423 (0)	366 (0)	2400 (0)	2034 (0)
	Permanent	113 (27.5)	39 (7.8)	44 (7.3)	20 (4.0)	20 (4.7)	26 (7.1)	149 (6.2)	123 (6.0)
	Persistent	93 (22.6)	104 (20.8)	111 (18.3)	137 (27.1)	136 (32.2)	101 (27.6)	589 (24.5)	488 (24.0)
	Paroxysmal	176 (42.8)	195 (39.1)	269 (44.4)	199 (39.3)	148 (35.0)	108 (29.5)	919 (38.3)	811 (39.9)
	New	29 (7.1)	161 (32.3)	182 (30.0)	150 (29.6)	119 (28.1)	131 (35.8)	743 (31.0)	612 (30.1)
Treatment Costs, n(%)	n (missing)	-	-	425 (0)	500 (0)	423 (0)	364 (0)	1712 (0)	1348 (0)

Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : POLAND

Variable	Statistics	Cohort 1 Retrospective patients (N=411) (n %)	Cohort 1 Prospective patients (N=499) (n %)	Cohort 2 (N=606) (n %)	Cohort 3 (N=506) (n %)	Cohort 4 (N=423) (n %)	Cohort 5 (N=366) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2400)	Total Prospective patients Cohorts 1 to 4 (N=2034)
	Public insurance	-	-	414 (97.4)	470 (94.0)	394 (93.1)	351 (96.4)	1629 (95.2)	1278 (94.8)
	Private (insurance)	-	-	5 (1.2)	1 (0.2)	1 (0.2)	-	7 (0.4)	7 (0.5)
	Private (out of pocke	-	-	1 (0.2)	7 (1.4)	7 (1.7)	8 (2.2)	23 (1.3)	15 (1.1)
	Combination	-	-	5 (1.2)	22 (4.4)	21 (5.0)	5 (1.4)	53 (3.1)	48 (3.6)
	Unknown	411	499	181	6	-	2	688	686
Treatment Sector, n(%)	n (missing)	9 (0)	-	425 (0)	502 (0)	423 (0)	366 (0)	1716 (0)	1350 (0)
	In the public sector	9 (100.0)	-	409 (96.2)	479 (95.4)	391 (92.4)	344 (94.0)	1623 (94.6)	1279 (94.7)
	In the private sector	-	-	16 (3.8)	23 (4.6)	32 (7.6)	22 (6.0)	93 (5.4)	71 (5.3)
	Unknown	402	499	181	4	-	-	684	684

Table 05 : Vital signs and life style
Full Analysis Dataset : POLAND

Variable	Statistics	Cohort 1 Retrospective patients (N=411) (n %)	Cohort 1 Prospective patients (N=499) (n %)	Cohort 2 (N=606) (n %)	Cohort 3 (N=506) (n %)	Cohort 4 (N=423) (n %)	Cohort 5 (N=366) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2400)	Total Prospective patients Cohorts 1 to 4 (N=2034)
Height (cm)	n (missing)	400 (11)	485 (14)	536 (70)	425 (81)	350 (73)	315 (51)	2111 (289)	1796 (238)
	Mean (SD)	168.2 (8.8)	168.2 (8.8)	168.6 (9.4)	168.7 (9.3)	168.7 (9.2)	169.4 (9.1)	168.7 (9.2)	168.5 (9.2)
	Median (IQR)	168.0 (162.0 to 176.0)	168.0 (162.0 to 175.0)	168.0 (162.0 to 175.0)	169.0 (162.0 to 175.0)	170.0 (162.0 to 176.0)	170.0 (164.0 to 176.0)	169.0 (162.0 to 175.0)	169.0 (162.0 to 175.0)
	Min to Max	137 to 193	146 to 195	140 to 198	140 to 193	145 to 195	146 to 194	140 to 198	140 to 198
Weight (kg)	n (missing)	400 (11)	485 (14)	536 (70)	425 (81)	350 (73)	315 (51)	2111 (289)	1796 (238)
	Mean (SD)	83.3 (15.8)	81.5 (17.1)	82.9 (16.6)	83.0 (16.3)	84.7 (17.2)	84.9 (20.3)	83.2 (17.4)	82.9 (16.8)
	Median (IQR)	84.0 (72.0 to 93.0)	80.0 (70.0 to 90.0)	82.0 (72.0 to 92.0)	81.0 (72.0 to 93.0)	82.0 (73.0 to 95.0)	81.0 (70.0 to 96.0)	82.0 (72.0 to 93.0)	82.0 (72.0 to 92.0)
	Min to Max	43 to 140	34 to 147	42 to 175	45 to 140	48 to 145	30 to 166	30 to 175	34 to 175
BMI (kg/m²)	n (missing)	400 (11)	485 (14)	536 (70)	425 (81)	350 (73)	315 (51)	2111 (289)	1796 (238)
	Mean (SD)	29.4 (4.9)	28.8 (5.3)	29.1 (5.0)	29.2 (5.3)	29.7 (5.4)	29.5 (5.9)	29.2 (5.3)	29.2 (5.2)
	Median (IQR)	29.0 (26.0 to 32.0)	28.0 (25.0 to 32.0)	29.0 (26.0 to 32.0)	29.0 (26.0 to 32.0)	29.0 (26.0 to 33.0)	28.0 (26.0 to 33.0)	29.0 (26.0 to 32.0)	29.0 (26.0 to 32.0)
	Min to Max	17 to 50	14 to 50	16 to 57	16 to 53	18 to 45	13 to 55	13 to 57	14 to 57
BMI Category, n(%)	n (missing)	400 (11)	485 (14)	536 (70)	425 (81)	350 (73)	315 (51)	2111 (289)	1796 (238)
	<19	1 (0.3)	7 (1.4)	3 (0.6)	7 (1.6)	1 (0.3)	3 (1.0)	21 (1.0)	18 (1.0)
	19-<25	69 (17.3)	106 (21.9)	103 (19.2)	85 (20.0)	65 (18.6)	64 (20.3)	423 (20.0)	359 (20.0)
	25-<30	164 (41.0)	203 (41.9)	218 (40.7)	160 (37.6)	132 (37.7)	120 (38.1)	833 (39.5)	713 (39.7)
	30-<40	156 (39.0)	157 (32.4)	197 (36.8)	157 (36.9)	134 (38.3)	108 (34.3)	753 (35.7)	645 (35.9)
	>=40	10 (2.5)	12 (2.5)	15 (2.8)	16 (3.8)	18 (5.1)	20 (6.3)	81 (3.8)	61 (3.4)
Pulse (bpm)	n (missing)	397 (14)	491 (8)	587 (19)	499 (7)	415 (8)	358 (8)	2350 (50)	1992 (42)
	Mean (SD)	81.3 (22.0)	86.0 (25.2)	88.5 (27.2)	90.3 (27.8)	88.3 (26.9)	90.3 (27.5)	88.6 (26.9)	88.3 (26.8)
	Median (IQR)	75.0 (68.0 to 90.0)	80.0 (70.0 to 100.0)	80.0 (70.0 to 100.0)	80.0 (70.0 to 110.0)	80.0 (70.0 to 100.0)	80.0 (70.0 to 105.0)	80.0 (70.0 to 100.0)	80.0 (70.0 to 100.0)
	Min to Max	50 to 163	40 to 200	42 to 200	47 to 200	40 to 180	30 to 170	30 to 200	40 to 200

Table 05 : Vital signs and life style
Full Analysis Dataset : POLAND

Variable	Statistics	Cohort 1 Retrospective patients (N=411) (n %)	Cohort 1 Prospective patients (N=499) (n %)	Cohort 2 (N=606) (n %)	Cohort 3 (N=506) (n %)	Cohort 4 (N=423) (n %)	Cohort 5 (N=366) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2400)	Total Prospective patients Cohorts 1 to 4 (N=2034)
Systolic BP (mm Hg)	n (missing)	398 (13)	490 (9)	592 (14)	496 (10)	414 (9)	355 (11)	2347 (53)	1992 (42)
	Mean (SD)	134.6 (18.6)	133.2 (18.1)	135.0 (19.7)	135.6 (20.3)	132.5 (18.7)	136.0 (17.8)	134.5 (19.1)	134.2 (19.3)
	Median (IQR)	130.0 (120.0 to 145.0)	130.0 (120.0 to 140.0)	130.0 (120.0 to 145.0)	130.0 (120.0 to 146.0)	130.0 (120.0 to 140.0)	130.0 (120.0 to 146.0)	130.0 (120.0 to 144.0)	130.0 (120.0 to 143.0)
	Min to Max	90 to 210	80 to 200	80 to 230	85 to 220	80 to 210	100 to 220	80 to 230	80 to 230
Diastolic BP (mm Hg)	n (missing)	398 (13)	490 (9)	592 (14)	496 (10)	414 (9)	355 (11)	2347 (53)	1992 (42)
	Mean (SD)	81.1 (11.2)	80.0 (10.3)	81.2 (11.1)	82.1 (12.1)	80.7 (11.4)	81.5 (10.9)	81.1 (11.2)	81.0 (11.3)
	Median (IQR)	80.0 (74.0 to 90.0)	80.0 (75.0 to 85.0)	80.0 (70.0 to 90.0)	80.0 (75.0 to 90.0)	80.0 (73.0 to 86.0)	80.0 (72.0 to 90.0)	80.0 (74.0 to 90.0)	80.0 (75.0 to 89.0)
	Min to Max	55 to 120	49 to 110	44 to 140	45 to 130	40 to 120	45 to 120	40 to 140	40 to 140
LVEF (%)	n (missing)	329 (82)	375 (124)	460 (146)	399 (107)	337 (86)	303 (63)	1874 (526)	1571 (463)
	Mean (SD)	54.3 (11.4)	55.0 (10.3)	54.0 (10.8)	52.7 (11.5)	52.5 (11.9)	52.9 (10.8)	53.5 (11.1)	53.6 (11.1)
	Median (IQR)	58.0 (50.0 to 60.0)	58.0 (50.0 to 60.0)	57.5 (50.0 to 60.0)	55.0 (47.0 to 60.0)	55.0 (45.0 to 60.0)	55.0 (47.0 to 60.0)	55.0 (50.0 to 60.0)	55.0 (50.0 to 60.0)
	Min to Max	20 to 75	19 to 77	15 to 85	10 to 76	15 to 77	15 to 75	10 to 85	10 to 85
LVEF Category, n(%)	n (missing)	329 (82)	375 (124)	460 (146)	399 (107)	337 (86)	303 (63)	1874 (526)	1571 (463)
	<40%	37 (11.2)	29 (7.7)	42 (9.1)	47 (11.8)	43 (12.8)	28 (9.2)	189 (10.1)	161 (10.2)
	>=40%	292 (88.8)	346 (92.3)	418 (90.9)	352 (88.2)	294 (87.2)	275 (90.8)	1685 (89.9)	1410 (89.8)
History of Hypertension, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	506 (0)	422 (0)	366 (0)	2399 (0)	2033 (0)
	No	63 (15.3)	70 (14.0)	86 (14.2)	57 (11.3)	59 (14.0)	36 (9.8)	308 (12.8)	272 (13.4)
	Yes	348 (84.7)	429 (86.0)	520 (85.8)	449 (88.7)	363 (86.0)	330 (90.2)	2091 (87.2)	1761 (86.6)

Table 05 : Vital signs and life style
Full Analysis Dataset : POLAND

Variable	Statistics	Cohort 1 Retrospective patients (N=411) (n %)	Cohort 1 Prospective patients (N=499) (n %)	Cohort 2 (N=606) (n %)	Cohort 3 (N=506) (n %)	Cohort 4 (N=423) (n %)	Cohort 5 (N=366) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2400)	Total Prospective patients Cohorts 1 to 4 (N=2034)
	Unknown	-	-	-	-	1	-	1	1
Alcohol Consumption, n(%)	n (missing)	407 (0)	491 (0)	573 (0)	488 (0)	398 (0)	358 (0)	2308 (0)	1950 (0)
	Abstinent	213 (52.3)	266 (54.2)	322 (56.2)	241 (49.4)	190 (47.7)	179 (50.0)	1198 (51.9)	1019 (52.3)
	Light	170 (41.8)	206 (42.0)	218 (38.0)	211 (43.2)	174 (43.7)	163 (45.5)	972 (42.1)	809 (41.5)
	Moderate	19 (4.7)	19 (3.9)	28 (4.9)	26 (5.3)	28 (7.0)	11 (3.1)	112 (4.9)	101 (5.2)
	Heavy	5 (1.2)	-	5 (0.9)	10 (2.0)	6 (1.5)	5 (1.4)	26 (1.1)	21 (1.1)
	Unknown	4	8	33	18	25	8	92	84
Smoker, n(%)	n (missing)	403 (0)	492 (0)	582 (0)	485 (0)	406 (0)	358 (0)	2323 (0)	1965 (0)
	No	252 (62.5)	315 (64.0)	373 (64.1)	317 (65.4)	282 (69.5)	231 (64.5)	1518 (65.3)	1287 (65.5)
	Ex-smoker	119 (29.5)	136 (27.6)	136 (23.4)	120 (24.7)	83 (20.4)	87 (24.3)	562 (24.2)	475 (24.2)
	Current smoker	32 (7.9)	41 (8.3)	73 (12.5)	48 (9.9)	41 (10.1)	40 (11.2)	243 (10.5)	203 (10.3)
	Unknown	8	7	24	21	17	8	77	69

Table 06 : Clinical History
Full Analysis Dataset : POLAND

Variable	Statistics	Cohort 1 Retrospective patients (N=411) (n %)	Cohort 1 Prospective patients (N=499) (n %)	Cohort 2 (N=606) (n %)	Cohort 3 (N=506) (n %)	Cohort 4 (N=423) (n %)	Cohort 5 (N=366) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2400)	Total Prospective patients Cohorts 1 to 4 (N=2034)
Congestive heart failure, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	506 (0)	423 (0)	366 (0)	2400 (0)	2034 (0)
	No	261 (63.5)	348 (69.7)	427 (70.5)	372 (73.5)	307 (72.6)	261 (71.3)	1715 (71.5)	1454 (71.5)
	Yes	150 (36.5)	151 (30.3)	179 (29.5)	134 (26.5)	116 (27.4)	105 (28.7)	685 (28.5)	580 (28.5)
Congestive Heart Failure NYHA Class, n(%)	n (missing)	150 (261)	151 (348)	176 (427)	130 (372)	105 (307)	94 (261)	656 (1715)	562 (1454)
	I	11 (7.3)	12 (7.9)	12 (6.8)	10 (7.7)	10 (9.5)	11 (11.7)	55 (8.4)	44 (7.8)
	II	100 (66.7)	90 (59.6)	109 (61.9)	65 (50.0)	55 (52.4)	51 (54.3)	370 (56.4)	319 (56.8)
	III	31 (20.7)	44 (29.1)	53 (30.1)	50 (38.5)	35 (33.3)	31 (33.0)	213 (32.5)	182 (32.4)
	IV	8 (5.3)	5 (3.3)	2 (1.1)	5 (3.8)	5 (4.8)	1 (1.1)	18 (2.7)	17 (3.0)
	Unknown	-	-	3	4	11	11	29	18
Coronary artery disease, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	506 (0)	423 (0)	366 (0)	2400 (0)	2034 (0)
	No	287 (69.8)	343 (68.7)	450 (74.3)	380 (75.1)	343 (81.1)	285 (77.9)	1801 (75.0)	1516 (74.5)
	Yes	124 (30.2)	156 (31.3)	156 (25.7)	126 (24.9)	80 (18.9)	81 (22.1)	599 (25.0)	518 (25.5)
Acute coronary syndrome, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	505 (0)	422 (0)	366 (0)	2398 (0)	2032 (0)
	No	361 (87.8)	414 (83.0)	536 (88.4)	455 (90.1)	380 (90.0)	334 (91.3)	2119 (88.4)	1785 (87.8)
	Yes	50 (12.2)	85 (17.0)	70 (11.6)	50 (9.9)	42 (10.0)	32 (8.7)	279 (11.6)	247 (12.2)
	Unknown	-	-	-	1	1	-	2	2
Carotid Occlusive Disease, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	494 (0)	418 (0)	364 (0)	2381 (0)	2017 (0)
	No	400 (97.3)	487 (97.6)	583 (96.2)	483 (97.8)	408 (97.6)	361 (99.2)	2322 (97.5)	1961 (97.2)

Table 06 : Clinical History
Full Analysis Dataset : POLAND

Variable	Statistics	Cohort 1 Retrospective patients (N=411) (n %)	Cohort 1 Prospective patients (N=499) (n %)	Cohort 2 (N=606) (n %)	Cohort 3 (N=506) (n %)	Cohort 4 (N=423) (n %)	Cohort 5 (N=366) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2400)	Total Prospective patients Cohorts 1 to 4 (N=2034)
	Yes	11 (2.7)	12 (2.4)	23 (3.8)	11 (2.2)	10 (2.4)	3 (0.8)	59 (2.5)	56 (2.8)
	Unknown	-	-	-	12	5	2	19	17
PE or DVT, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	505 (0)	422 (0)	365 (0)	2397 (0)	2032 (0)
	No	404 (98.3)	492 (98.6)	594 (98.0)	494 (97.8)	414 (98.1)	356 (97.5)	2350 (98.0)	1994 (98.1)
	Yes	7 (1.7)	7 (1.4)	12 (2.0)	11 (2.2)	8 (1.9)	9 (2.5)	47 (2.0)	38 (1.9)
	Unknown	-	-	-	1	1	1	3	2
Other Thromboembolism, n(%)	n (missing)	411 (0)	499 (0)	601 (5)	0 (506)	0 (423)	0 (366)	1100 (1300)	1100 (934)
	No	394 (95.9)	490 (98.2)	594 (98.8)	-	-	-	1084 (98.5)	1084 (98.5)
	Yes	17 (4.1)	9 (1.8)	7 (1.2)	-	-	-	16 (1.5)	16 (1.5)
Systemic Embolization, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	504 (0)	421 (0)	366 (0)	2396 (0)	2030 (0)
	No	407 (99.0)	499 (100.0)	604 (99.7)	500 (99.2)	421 (100.0)	365 (99.7)	2389 (99.7)	2024 (99.7)
	Yes	4 (1.0)	-	2 (0.3)	4 (0.8)	-	1 (0.3)	7 (0.3)	6 (0.3)
	Unknown	-	-	-	2	2	-	4	4
Coronary Artery Bypass Graft, n(%)	n (missing)	310 (0)	381 (0)	606 (0)	505 (0)	423 (0)	366 (0)	2281 (0)	1915 (0)
	No	309 (99.7)	377 (99.0)	595 (98.2)	494 (97.8)	410 (96.9)	354 (96.7)	2230 (97.8)	1876 (98.0)
	Yes	1 (0.3)	4 (1.0)	11 (1.8)	11 (2.2)	13 (3.1)	12 (3.3)	51 (2.2)	39 (2.0)
	Unknown	101	118	-	1	-	-	119	119
Stroke/TIA, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	506 (0)	423 (0)	366 (0)	2400 (0)	2034 (0)

Table 06 : Clinical History
Full Analysis Dataset : POLAND

Variable	Statistics	Cohort 1 Retrospective patients (N=411) (n %)	Cohort 1 Prospective patients (N=499) (n %)	Cohort 2 (N=606) (n %)	Cohort 3 (N=506) (n %)	Cohort 4 (N=423) (n %)	Cohort 5 (N=366) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2400)	Total Prospective patients Cohorts 1 to 4 (N=2034)
	No	369 (89.8)	465 (93.2)	558 (92.1)	460 (90.9)	396 (93.6)	338 (92.3)	2217 (92.4)	1879 (92.4)
	Yes	42 (10.2)	34 (6.8)	48 (7.9)	46 (9.1)	27 (6.4)	28 (7.7)	183 (7.6)	155 (7.6)
Stroke, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	506 (0)	423 (0)	366 (0)	2400 (0)	2034 (0)
	No	380 (92.5)	475 (95.2)	575 (94.9)	477 (94.3)	405 (95.7)	351 (95.9)	2283 (95.1)	1932 (95.0)
	Yes	31 (7.5)	24 (4.8)	31 (5.1)	29 (5.7)	18 (4.3)	15 (4.1)	117 (4.9)	102 (5.0)
History of Bleeding, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	505 (0)	421 (0)	366 (0)	2397 (0)	2031 (0)
	No	385 (93.7)	484 (97.0)	589 (97.2)	493 (97.6)	412 (97.9)	361 (98.6)	2339 (97.6)	1978 (97.4)
	Yes	26 (6.3)	15 (3.0)	17 (2.8)	12 (2.4)	9 (2.1)	5 (1.4)	58 (2.4)	53 (2.6)
	Unknown	-	-	-	1	2	-	3	3
Hypercholesterolaemia, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	468 (0)	396 (0)	341 (0)	2310 (0)	1969 (0)
	No	187 (45.5)	246 (49.3)	269 (44.4)	218 (46.6)	163 (41.2)	150 (44.0)	1046 (45.3)	896 (45.5)
	Yes	224 (54.5)	253 (50.7)	337 (55.6)	250 (53.4)	233 (58.8)	191 (56.0)	1264 (54.7)	1073 (54.5)
	Unknown	-	-	-	38	27	25	90	65
Diabetes, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	506 (0)	423 (0)	366 (0)	2400 (0)	2034 (0)
	No	313 (76.2)	384 (77.0)	477 (78.7)	393 (77.7)	323 (76.4)	270 (73.8)	1847 (77.0)	1577 (77.5)
	Type I	4 (1.0)	6 (1.2)	5 (0.8)	4 (0.8)	2 (0.5)	3 (0.8)	20 (0.8)	17 (0.8)
	Type II	94 (22.9)	109 (21.8)	124 (20.5)	109 (21.5)	98 (23.2)	93 (25.4)	533 (22.2)	440 (21.6)
Diabetes, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	506 (0)	423 (0)	366 (0)	2400 (0)	2034 (0)
	No	313 (76.2)	384 (77.0)	477 (78.7)	393 (77.7)	323 (76.4)	270 (73.8)	1847 (77.0)	1577 (77.5)
	Yes	98 (23.8)	115 (23.0)	129 (21.3)	113 (22.3)	100 (23.6)	96 (26.2)	553 (23.0)	457 (22.5)
Cirrhosis, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	490 (0)	417 (0)	355 (0)	2367 (0)	2012 (0)
	No	409 (99.5)	497 (99.6)	600 (99.0)	489 (99.8)	414 (99.3)	355 (100.0)	2355 (99.5)	2000 (99.4)
	Yes	2 (0.5)	2 (0.4)	6 (1.0)	1 (0.2)	3 (0.7)	-	12 (0.5)	12 (0.6)

Table 06 : Clinical History
Full Analysis Dataset : POLAND

Variable	Statistics	Cohort 1 Retrospective patients (N=411) (n %)	Cohort 1 Prospective patients (N=499) (n %)	Cohort 2 (N=606) (n %)	Cohort 3 (N=506) (n %)	Cohort 4 (N=423) (n %)	Cohort 5 (N=366) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2400)	Total Prospective patients Cohorts 1 to 4 (N=2034)
	Unknown	-	-	-	16	6	11	33	22
Dementia, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	505 (0)	422 (0)	366 (0)	2398 (0)	2032 (0)
	No	399 (97.1)	486 (97.4)	587 (96.9)	503 (99.6)	415 (98.3)	361 (98.6)	2352 (98.1)	1991 (98.0)
	Yes	12 (2.9)	13 (2.6)	19 (3.1)	2 (0.4)	7 (1.7)	5 (1.4)	46 (1.9)	41 (2.0)
	Unknown	-	-	-	1	1	-	2	2
Hyperthyroidism, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	492 (0)	407 (0)	353 (0)	2357 (0)	2004 (0)
	No	398 (96.8)	492 (98.6)	586 (96.7)	482 (98.0)	399 (98.0)	349 (98.9)	2308 (97.9)	1959 (97.8)
	Yes	13 (3.2)	7 (1.4)	20 (3.3)	10 (2.0)	8 (2.0)	4 (1.1)	49 (2.1)	45 (2.2)
	Unknown	-	-	-	14	16	13	43	30
Hypothyroidism, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	489 (0)	407 (0)	353 (0)	2354 (0)	2001 (0)
	No	391 (95.1)	483 (96.8)	577 (95.2)	457 (93.5)	380 (93.4)	331 (93.8)	2228 (94.6)	1897 (94.8)
	Yes	20 (4.9)	16 (3.2)	29 (4.8)	32 (6.5)	27 (6.6)	22 (6.2)	126 (5.4)	104 (5.2)
	Unknown	-	-	-	17	16	13	46	33
Vascular Disease, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	505 (1)	422 (1)	366 (0)	2398 (2)	2032 (2)
	No	337 (82.0)	377 (75.6)	496 (81.8)	426 (84.4)	367 (87.0)	320 (87.4)	1986 (82.8)	1666 (82.0)
	Yes	74 (18.0)	122 (24.4)	110 (18.2)	79 (15.6)	55 (13.0)	46 (12.6)	412 (17.2)	366 (18.0)
Moderate to Severe CKD, n(%)	n (missing)	411 (0)	499 (0)	606 (0)	506 (0)	423 (0)	366 (0)	2400 (0)	2034 (0)
	No	373 (90.8)	430 (86.2)	522 (86.1)	438 (86.6)	372 (87.9)	315 (86.1)	2077 (86.5)	1762 (86.6)
	Yes	38 (9.2)	69 (13.8)	84 (13.9)	68 (13.4)	51 (12.1)	51 (13.9)	323 (13.5)	272 (13.4)

Table 07 : Treatment for stroke prophylaxis
Full Analysis Dataset : POLAND

Variable	Statistics	Cohort 1 Retrospective patients (N=411) (n %)	Cohort 1 Prospective patients (N=499) (n %)	Cohort 2 (N=606) (n %)	Cohort 3 (N=506) (n %)	Cohort 4 (N=423) (n %)	Cohort 5 (N=366) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2400)	Total Prospective patients Cohorts 1 to 4 (N=2034)
Baseline Treatment, n(%)	n (missing)	388 (0)	447 (0)	603 (0)	498 (0)	420 (0)	362 (0)	2330 (0)	1968 (0)
	VKA	192 (49.5)	157 (35.1)	222 (36.8)	137 (27.5)	73 (17.4)	40 (11.0)	629 (27.0)	589 (29.9)
	VKA+AP	72 (18.6)	98 (21.9)	98 (16.3)	38 (7.6)	18 (4.3)	4 (1.1)	256 (11.0)	252 (12.8)
	FXA	2 (0.5)	8 (1.8)	37 (6.1)	78 (15.7)	108 (25.7)	133 (36.7)	364 (15.6)	231 (11.7)
	FXA+AP	12 (3.1)	14 (3.1)	10 (1.7)	9 (1.8)	14 (3.3)	9 (2.5)	56 (2.4)	47 (2.4)
	DTI	-	-	27 (4.5)	106 (21.3)	138 (32.9)	120 (33.1)	391 (16.8)	271 (13.8)
	DTI+AP	-	-	3 (0.5)	8 (1.6)	12 (2.9)	10 (2.8)	33 (1.4)	23 (1.2)
	AP	94 (24.2)	135 (30.2)	144 (23.9)	66 (13.3)	27 (6.4)	19 (5.2)	391 (16.8)	372 (18.9)
	NONE	16 (4.1)	35 (7.8)	62 (10.3)	56 (11.2)	30 (7.1)	27 (7.5)	210 (9.0)	183 (9.3)
	Unknown	23	52	3	8	3	4	70	66
	VKA±AP	264 (68.0)	255 (57.0)	320 (53.1)	175 (35.1)	91 (21.7)	44 (12.2)	885 (38.0)	841 (42.7)
	FXA±AP	14 (3.6)	22 (4.9)	47 (7.8)	87 (17.5)	122 (29.0)	142 (39.2)	420 (18.0)	278 (14.1)
	DTI±AP	-	-	30 (5.0)	114 (22.9)	150 (35.7)	130 (35.9)	424 (18.2)	294 (14.9)
	FXA/DTI	2 (0.5)	8 (1.8)	64 (10.6)	184 (36.9)	246 (58.6)	253 (69.9)	755 (32.4)	502 (25.5)
	FXA/DTI+AP	12 (3.1)	14 (3.1)	13 (2.2)	17 (3.4)	26 (6.2)	19 (5.2)	89 (3.8)	70 (3.6)
	FXA/DTI±AP	14 (3.6)	22 (4.9)	77 (12.8)	201 (40.4)	272 (64.8)	272 (75.1)	844 (36.2)	572 (29.1)
	AC	194 (50.0)	165 (36.9)	286 (47.4)	321 (64.5)	319 (76.0)	293 (80.9)	1384 (59.4)	1091 (55.4)
	AC+AP	84 (21.6)	112 (25.1)	111 (18.4)	55 (11.0)	44 (10.5)	23 (6.4)	345 (14.8)	322 (16.4)
	AC±AP	278 (71.6)	277 (62.0)	397 (65.8)	376 (75.5)	363 (86.4)	316 (87.3)	1729 (74.2)	1413 (71.8)

Table 08: Treatment
Full Analysis Dataset : POLAND

	Cohort 1 Retrospective (N=411) (n %)	Cohort 1 Prospective (N=499) (n %)	Cohort 2 (N=606) (n %)	Cohort 3 (N=506) (n %)	Cohort 4 (N=423) (n %)	Cohort 5 (N=366) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2400)	Total Prospective patients Cohorts 1 to 4 (N=2034)
Anti-platelet (non mutually exclusive groups)								
Glycoprotein inhibitors	-	-	1 (0.2)	1 (0.2)	-		2 (0.1)	2 (0.1)
ADP receptor/P2Y12 inhibitors	10 (2.4)	22 (4.4)	20 (3.3)	31 (6.1)	12 (2.8)	13 (3.6)	98 (4.1)	85 (4.2)
Cox inhibitors	32 (7.8)	34 (6.8)	1 (0.2)	22 (4.3)	11 (2.6)	2 (0.5)	70 (2.9)	68 (3.3)
ASA	114 (27.7)	147 (29.5)	218 (36.0)	104 (20.6)	62 (14.7)	37 (10.1)	568 (23.7)	531 (26.1)
Anticoagulant drugs (non mutually exclusive groups)								
VKA	269 (65.5)	280 (56.1)	323 (53.3)	181 (35.8)	92 (21.7)	47 (12.8)	923 (38.5)	876 (43.1)
FXa	20 (4.9)	47 (9.4)	50 (8.3)	90 (17.8)	123 (29.1)	146 (39.9)	456 (19.0)	310 (15.2)
DTI	1 (0.2)	-	30 (5.0)	121 (23.9)	152 (35.9)	131 (35.8)	434 (18.1)	303 (14.9)
Heparinoid	-	3 (0.6)	-	-	1 (0.2)		4 (0.2)	4 (0.2)
Heparins	19 (4.6)	34 (6.8)	126 (20.8)	77 (15.2)	37 (8.7)	20 (5.5)	294 (12.3)	274 (13.5)
Other	-	-	1 (0.2)	-	-	1 (0.3)	2 (0.1)	1 (0.0)

Table 09 : Risk scores
Full Analysis Dataset : POLAND

Variable	Statistics	Cohort 1 Retrospective patients (N=411) (n %)	Cohort 1 Prospective patients (N=499) (n %)	Cohort 2 (N=606) (n %)	Cohort 3 (N=506) (n %)	Cohort 4 (N=423) (n %)	Cohort 5 (N=366) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2400)	Total Prospective patients Cohorts 1 to 4 (N=2034)
CHADS2 Score	n (missing)	407 (4)	496 (3)	606 (0)	505 (1)	420 (3)	363 (3)	2390 (10)	2027 (7)
	Mean (SD)	1.9 (1.1)	1.9 (1.1)	1.9 (1.1)	1.9 (1.1)	1.8 (1.1)	1.9 (1.0)	1.9 (1.1)	1.9 (1.1)
	Median (IQR)	2.0 (1.0 to 3.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.5)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)
	Min to Max	0 to 6	0 to 6	0 to 6	0 to 6	0 to 6	0 to 6	0 to 6	0 to 6
CHADS2 score categories, n(%)	n (missing)	407 (4)	496 (3)	606 (0)	505 (1)	420 (3)	363 (3)	2390 (10)	2027 (7)
	0	13 (3.2)	27 (5.4)	34 (5.6)	23 (4.6)	27 (6.4)	13 (3.6)	124 (5.2)	111 (5.5)
	1	158 (38.8)	188 (37.9)	238 (39.3)	186 (36.8)	165 (39.3)	139 (38.3)	916 (38.3)	777 (38.3)
	2	128 (31.4)	161 (32.5)	185 (30.5)	179 (35.4)	123 (29.3)	122 (33.6)	770 (32.2)	648 (32.0)
	3	76 (18.7)	83 (16.7)	98 (16.2)	80 (15.8)	78 (18.6)	61 (16.8)	400 (16.7)	339 (16.7)
	4	23 (5.7)	28 (5.6)	37 (6.1)	22 (4.4)	20 (4.8)	22 (6.1)	129 (5.4)	107 (5.3)
	5	6 (1.5)	6 (1.2)	11 (1.8)	14 (2.8)	5 (1.2)	5 (1.4)	41 (1.7)	36 (1.8)
	6	3 (0.7)	3 (0.6)	3 (0.5)	1 (0.2)	2 (0.5)	1 (0.3)	10 (0.4)	9 (0.4)
CHA2DS2-VASc Score	n (missing)	407 (4)	496 (3)	606 (0)	502 (4)	418 (5)	363 (3)	2385 (15)	2022 (12)
	Mean (SD)	3.2 (1.6)	3.2 (1.7)	3.1 (1.7)	3.2 (1.6)	3.0 (1.6)	3.1 (1.5)	3.1 (1.6)	3.1 (1.6)
	Median (IQR)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)
	Min to Max	0 to 8	0 to 9	0 to 8	0 to 9	0 to 8	0 to 8	0 to 9	0 to 9
CHA2DS2-VASc score categories, n(%)	n (missing)	407 (4)	496 (3)	606 (0)	502 (4)	418 (5)	363 (3)	2385 (15)	2022 (12)
	0	4 (1.0)	7 (1.4)	16 (2.6)	6 (1.2)	12 (2.9)	3 (0.8)	44 (1.8)	41 (2.0)
	1	56 (13.8)	72 (14.5)	108 (17.8)	75 (14.9)	63 (15.1)	47 (12.9)	365 (15.3)	318 (15.7)
	2	95 (23.3)	106 (21.4)	114 (18.8)	112 (22.3)	98 (23.4)	90 (24.8)	520 (21.8)	430 (21.3)
	3	96 (23.6)	93 (18.8)	130 (21.5)	103 (20.5)	83 (19.9)	87 (24.0)	496 (20.8)	409 (20.2)
	4	75 (18.4)	112 (22.6)	119 (19.6)	108 (21.5)	84 (20.1)	79 (21.8)	502 (21.0)	423 (20.9)

Table 09 : Risk scores
Full Analysis Dataset : POLAND

Variable	Statistics	Cohort 1 Retrospective patients (N=411) (n %)	Cohort 1 Prospective patients (N=499) (n %)	Cohort 2 (N=606) (n %)	Cohort 3 (N=506) (n %)	Cohort 4 (N=423) (n %)	Cohort 5 (N=366) (n %)	Total Prospective patients Cohorts 1 to 5 (N=2400)	Total Prospective patients Cohorts 1 to 4 (N=2034)
	5	46 (11.3)	66 (13.3)	63 (10.4)	61 (12.2)	56 (13.4)	33 (9.1)	279 (11.7)	246 (12.2)
	6-9	35 (8.6)	40 (8.1)	56 (9.2)	37 (7.4)	22 (5.3)	24 (6.6)	179 (7.5)	155 (7.7)
HAS-BLED score	n (missing)	336 (75)	425 (74)	484 (122)	452 (54)	386 (37)	339 (27)	2086 (314)	1747 (287)
	Mean (SD)	1.3 (1.0)	1.4 (0.9)	1.3 (1.0)	1.3 (0.9)	1.1 (0.9)	1.1 (0.9)	1.3 (0.9)	1.3 (0.9)
	Median (IQR)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (0.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)
	Min to Max	0 to 5	0 to 5	0 to 5	0 to 4	0 to 4	0 to 4	0 to 5	0 to 5
HAS-BLED score categories, n(%)	n (missing)	336 (75)	425 (74)	484 (122)	452 (54)	386 (37)	339 (27)	2086 (314)	1747 (287)
	0	75 (22.3)	53 (12.5)	98 (20.2)	93 (20.6)	99 (25.6)	82 (24.2)	425 (20.4)	343 (19.6)
	1	126 (37.5)	195 (45.9)	198 (40.9)	173 (38.3)	174 (45.1)	159 (46.9)	899 (43.1)	740 (42.4)
	2	103 (30.7)	133 (31.3)	132 (27.3)	146 (32.3)	91 (23.6)	75 (22.1)	577 (27.7)	502 (28.7)
	3	25 (7.4)	41 (9.6)	46 (9.5)	35 (7.7)	16 (4.1)	21 (6.2)	159 (7.6)	138 (7.9)
	4	6 (1.8)	2 (0.5)	8 (1.7)	5 (1.1)	6 (1.6)	2 (0.6)	23 (1.1)	21 (1.2)
	5	1 (0.3)	1 (0.2)	2 (0.4)	-	-	-	3 (0.1)	3 (0.2)

Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : POLAND

		VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
Cohort	**CHA2DS2-VAsc**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**
Cohort 1 retrospective	0	2	50	-	-	-	-	-	-	-	-	-	-	-	-	2	50	-
	1	32	61.5	5	9.6	-	-	-	-	-	-	-	-	13	25	2	3.8	4
	2	47	51.6	18	19.8	-	-	2	2.2	-	-	-	-	22	24.2	2	2.2	4
	3	44	47.3	14	15.1	2	2.2	3	3.2	-	-	-	-	26	28	4	4.3	3
	4	32	47.1	16	23.5	-	-	1	1.5	-	-	-	-	15	22.1	4	5.9	7
	5	19	42.2	12	26.7	-	-	3	6.7	-	-	-	-	10	22.2	1	2.2	1
	6-9	13	41.9	7	22.6	-	-	3	9.7	-	-	-	-	7	22.6	1	3.2	4
Cohort 1 prospective	0	-	-	1	14.3	-	-	1	14.3	-	-	-	-	4	57.1	1	14.3	-
	1	22	36.1	10	16.4	-	-	-	-	-	-	-	-	24	39.3	5	8.2	11
	2	32	36	19	21.3	-	-	2	2.2	-	-	-	-	30	33.7	6	6.7	17
	3	35	42.2	23	27.7	-	-	1	1.2	-	-	-	-	14	16.9	10	12	10
	4	41	39.4	23	22.1	4	3.8	4	3.8	-	-	-	-	26	25	6	5.8	8
	5	19	30.2	14	22.2	4	6.3	3	4.8	-	-	-	-	17	27	6	9.5	3
	6-9	7	18.9	8	21.6	-	-	3	8.1	-	-	-	-	18	48.6	1	2.7	3
Cohort 2	0	5	31.3	-	-	2	12.5	-	-	1	6.3	-	-	4	25	4	25	-
	1	45	41.7	7	6.5	5	4.6	1	0.9	8	7.4	1	0.9	26	24.1	15	13.9	-
	2	46	40.4	17	14.9	5	4.4	-	-	6	5.3	1	0.9	25	21.9	14	12.3	-
	3	49	38	19	14.7	11	8.5	2	1.6	6	4.7	-	-	32	24.8	10	7.8	1
	4	51	42.9	22	18.5	6	5	2	1.7	4	3.4	-	-	27	22.7	7	5.9	-
	5	14	23	15	24.6	4	6.6	4	6.6	2	3.3	-	-	15	24.6	7	11.5	2
	6-9	12	21.4	18	32.1	4	7.1	1	1.8	-	-	1	1.8	15	26.8	5	8.9	-
Cohort 3	0	-	-	-	-	-	-	-	-	-	-	-	-	1	20	4	80	1
	1	18	24	-	-	10	13.3	-	-	20	26.7	-	-	13	17.3	14	18.7	-
	2	35	31.5	5	4.5	14	12.6	3	2.7	28	25.2	1	0.9	12	10.8	13	11.7	1
	3	31	30.4	7	6.9	19	18.6	2	2	22	21.6	2	2	11	10.8	8	7.8	1
	4	29	27.6	11	10.5	14	13.3	1	1	20	19	3	2.9	15	14.3	12	11.4	3

Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : POLAND

		VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
Cohort	**CHA2DS2-VAsc**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**
	5	14	23.3	8	13.3	15	25	1	1.7	11	18.3	1	1.7	8	13.3	2	3.3	1
	6-9	10	27.8	7	19.4	4	11.1	2	5.6	4	11.1	1	2.8	6	16.7	2	5.6	1
Cohort 4	0	1	8.3	-	-	2	16.7	-	-	8	66.7	-	-	-	-	1	8.3	-
	1	8	12.9	-	-	9	14.5	-	-	33	53.2	1	1.6	7	11.3	4	6.5	1
	2	18	18.6	3	3.1	19	19.6	3	3.1	36	37.1	4	4.1	6	6.2	8	8.2	1
	3	18	21.7	4	4.8	29	34.9	3	3.6	18	21.7	1	1.2	3	3.6	7	8.4	-
	4	14	16.9	7	8.4	24	28.9	4	4.8	22	26.5	3	3.6	3	3.6	6	7.2	1
	5	8	14.3	2	3.6	16	28.6	3	5.4	14	25	3	5.4	6	10.7	4	7.1	-
	6-9	4	18.2	2	9.1	8	36.4	1	4.5	6	27.3	-	-	1	4.5	-	-	-
Cohort 5	0	-	-	-	-	1	33.3	-	-	1	33.3	-	-	-	-	1	33.3	-
	1	7	15.2	-	-	8	17.4	-	-	22	47.8	-	-	4	8.7	5	10.9	1
	2	12	13.3	-	-	42	46.7	-	-	25	27.8	1	1.1	2	2.2	8	8.9	-
	3	8	9.4	-	-	36	42.4	2	2.4	30	35.3	3	3.5	3	3.5	3	3.5	2
	4	8	10.3	2	2.6	29	37.2	4	5.1	21	26.9	4	5.1	3	3.8	7	9	1
	5	3	9.1	1	3	8	24.2	-	-	13	39.4	1	3	4	12.1	3	9.1	-
	6-9	2	8.3	-	-	9	37.5	2	8.3	8	33.3	1	4.2	2	8.3	-	-	-
Total Prospective patients Cohorts 1 to 5	0	6	14	1	2.3	5	11.6	1	2.3	10	23.3	-	-	9	20.9	11	25.6	1
	1	100	28.4	17	4.8	32	9.1	1	0.3	83	23.6	2	0.6	74	21	43	12.2	13
	2	143	28.5	44	8.8	80	16	8	1.6	95	19	7	1.4	75	15	49	9.8	19
	3	141	29.3	53	11	95	19.7	10	2.1	76	15.8	6	1.2	63	13.1	38	7.9	14
	4	143	29.2	65	13.3	77	15.7	15	3.1	67	13.7	10	2	74	15.1	38	7.8	13
	5	58	21.2	40	14.7	47	17.2	11	4	40	14.7	5	1.8	50	18.3	22	8.1	6
	6-9	35	20	35	20	25	14.3	9	5.1	18	10.3	3	1.7	42	24	8	4.6	4

Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : POLAND

		VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
Cohort	**CHA2DS2-VAsc**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**
Total Prospective patients Cohorts 1 to 4	0	6	15	1	2.5	4	10	1	2.5	9	22.5	-	-	9	22.5	10	25	1
	1	93	30.4	17	5.6	24	7.8	1	0.3	61	19.9	2	0.7	70	22.9	38	12.4	12
	2	131	31.9	44	10.7	38	9.2	8	1.9	70	17	6	1.5	73	17.8	41	10	19
	3	133	33.5	53	13.4	59	14.9	8	2	46	11.6	3	0.8	60	15.1	35	8.8	12
	4	135	32.8	63	15.3	48	11.7	11	2.7	46	11.2	6	1.5	71	17.3	31	7.5	12
	5	55	22.9	39	16.3	39	16.3	11	4.6	27	11.3	4	1.7	46	19.2	19	7.9	6
	6-9	33	21.9	35	23.2	16	10.6	7	4.6	10	6.6	2	1.3	40	26.5	8	5.3	4

Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : POLAND

		VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
Cohort	**HAS-BLED**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**
Cohort 1 retrospective	0	69	95.8	-	-	-	-	-	-	-	-	-	-	-	-	3	4.2	3
	1	68	56.2	22	18.2	1	0.8	-	-	-	-	-	-	27	22.3	3	2.5	5
	2	26	26.5	27	27.6	-	-	5	5.1	-	-	-	-	36	36.7	4	4.1	5
	3	6	24	5	20	-	-	3	12	-	-	-	-	11	44	-	-	-
	4-9	1	14.3	1	14.3	-	-	-	-	-	-	-	-	4	57.1	1	14.3	-
Cohort 1 prospective	0	38	90.5	-	-	-	-	-	-	-	-	-	-	-	-	4	9.5	11
	1	75	43.6	30	17.4	3	1.7	2	1.2	-	-	-	-	53	30.8	9	5.2	23
	2	27	21.3	41	32.3	3	2.4	6	4.7	-	-	-	-	44	34.6	6	4.7	6
	3	-	-	12	32.4	-	-	1	2.7	-	-	-	-	21	56.8	3	8.1	4
	4-9	-	-	2	66.7	-	-	1	33.3	-	-	-	-	-	-	-	-	-
Cohort 2	0	68	69.4	-	-	7	7.1	-	-	9	9.2	-	-	-	-	14	14.3	-
	1	82	41.4	30	15.2	16	8.1	3	1.5	13	6.6	2	1	44	22.2	8	4	-
	2	35	26.7	34	26	2	1.5	3	2.3	1	0.8	1	0.8	50	38.2	5	3.8	1
	3	5	11.4	12	27.3	2	4.5	2	4.5	-	-	-	-	20	45.5	3	6.8	2
	4-9	1	10	4	40	-	-	-	-	-	-	-	-	4	40	1	10	-
Cohort 3	0	29	31.5	-	-	16	17.4	-	-	31	33.7	-	-	-	-	16	17.4	1
	1	59	34.5	5	2.9	25	14.6	1	0.6	42	24.6	2	1.2	15	8.8	22	12.9	2
	2	30	21.1	18	12.7	18	12.7	6	4.2	24	16.9	4	2.8	32	22.5	10	7	4
	3	5	14.7	4	11.8	8	23.5	1	2.9	4	11.8	2	5.9	8	23.5	2	5.9	1
	4-9	-	-	3	60	1	20	-	-	-	-	-	-	1	20	-	-	-
Cohort 4	0	15	15.3	-	-	20	20.4	-	-	52	53.1	-	-	-	-	11	11.2	1
	1	35	20.2	6	3.5	55	31.8	5	2.9	53	30.6	4	2.3	10	5.8	5	2.9	1
	2	12	13.3	5	5.6	21	23.3	7	7.8	22	24.4	5	5.6	9	10	9	10	1
	3	2	12.5	2	12.5	2	12.5	1	6.3	1	6.3	3	18.8	4	25	1	6.3	-
	4-9	-	-	3	50	1	16.7	-	-	-	-	-	-	2	33.3	-	-	-

Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : POLAND

		VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
Cohort	**HAS-BLED**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**
Cohort 5	0	8	9.9	-	-	32	39.5	-	-	34	42	-	-	-	-	7	8.6	1
	1	20	12.7	-	-	60	38	1	0.6	57	36.1	2	1.3	5	3.2	13	8.2	1
	2	9	12.2	1	1.4	26	35.1	4	5.4	21	28.4	4	5.4	4	5.4	5	6.8	1
	3	-	-	2	10	4	20	1	5	5	25	3	15	5	25	-	-	1
	4-9	-	-	-	-	-	-	-	-	-	-	1	50	1	50	-	-	-
Total Prospective patients Cohorts 1 to 5	0	158	38.4	-	-	75	18.2	-	-	126	30.7	-	-	-	-	52	12.7	14
	1	271	31.1	71	8.1	159	18.2	12	1.4	165	18.9	10	1.1	127	14.6	57	6.5	27
	2	113	20	99	17.6	70	12.4	26	4.6	68	12.1	14	2.5	139	24.6	35	6.2	13
	3	12	7.9	32	21.2	16	10.6	6	4	10	6.6	8	5.3	58	38.4	9	6	8
	4-9	1	3.8	12	46.2	2	7.7	1	3.8	-	-	1	3.8	8	30.8	1	3.8	-
Total Prospective patients Cohorts 1 to 4	0	150	45.5	-	-	43	13	-	-	92	27.9	-	-	-	-	45	13.6	13
	1	251	35.2	71	9.9	99	13.9	11	1.5	108	15.1	8	1.1	122	17.1	44	6.2	26
	2	104	21.2	98	20	44	9	22	4.5	47	9.6	10	2	135	27.6	30	6.1	12
	3	12	9.2	30	22.9	12	9.2	5	3.8	5	3.8	5	3.8	53	40.5	9	6.9	7
	4-9	1	4.2	12	50	2	8.3	1	4.2	-	-	-	-	7	29.2	1	4.2	-

Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4 Full Analysis Dataset : POLAND

Variable	Statistics	Cohort 1 Prospective patients (N=255) (n %)	Cohort 2 (N=320) (n %)	Cohort 3 (N=175) (n %)	Cohort 4 (N=91) (n %)	Total Prospective patients Cohorts 1 to 4 (N=841)
TTR value, n(%)	n (missing)	147 (108)	193 (127)	79 (96)	40 (51)	459 (382)
	<65	92 (62.6)	106 (54.9)	48 (60.8)	25 (62.5)	271 (59.0)
	>=65	55 (37.4)	87 (45.1)	31 (39.2)	15 (37.5)	188 (41.0)
TTR	n (missing)	147 (108)	193 (127)	79 (96)	40 (51)	459 (382)
	Mean (SD)	53.3 (28.6)	60.6 (25.5)	55.5 (26.5)	54.0 (27.9)	56.8 (27.0)
	Median (IQR)	57.2 (33.2 to 75.3)	62.4 (41.5 to 79.9)	57.3 (37.7 to 75.0)	56.1 (32.7 to 75.4)	59.3 (39.2 to 77.8)
	Min to Max	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0
INR value, n(%)	n	1353	1995	811	407	4566
	2-3	633 (46.8)	1028 (51.5)	386 (47.6)	206 (50.6)	2253 (49.3)
	<2	472 (34.9)	667 (33.4)	278 (34.3)	120 (29.5)	1537 (33.7)
	>3	248 (18.3)	300 (15.0)	147 (18.1)	81 (19.9)	776 (17.0)
INR	n	1353	1995	811	407	4566
	Mean (SD)	2.4 (1.0)	2.3 (0.8)	2.4 (1.0)	2.5 (1.1)	2.4 (0.9)
	Median (IQR)	2.2 (1.8 to 2.8)	2.2 (1.8 to 2.7)	2.3 (1.8 to 2.8)	2.4 (1.9 to 2.9)	2.3 (1.8 to 2.8)
	Min to Max	0.9 to 12.0	0.8 to 12.0	0.9 to 11.6	0.9 to 10.2	0.8 to 12.0

Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : POLAND

Outcome	Cause	N	Events	Event rate /100 person-years	95% CI
All-cause death		2034	54	2.78	(2.13 to 3.63)
	Cardiovascular death	2034	26	1.34	(0.91 to 1.97)
	Non-Cardiovascular death	2034	12	0.62	(0.35 to 1.09)
	Undetermined cause	2034	16	0.82	(0.51 to 1.35)
Stroke/SE		2034	18	0.93	(0.59 to 1.48)
Major bleed		2034	9	0.46	(0.24 to 0.89)
Acute coronary syndrome		2034	21	1.09	(0.71 to 1.67)
Congestive Heart Failure		2034	57	2.99	(2.31 to 3.88)

Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : POLAND

		POLAND		
Outcome	**Cause**	**N**	**Events**	**%**
Cardiovascular causes	Myocardial infarction	26	3	11.54
	Ischaemic stroke	26	6	23.08
	Congestive heart failure	26	7	26.92
	Sudden or unwitnessed death	26	5	19.23
	Other	26	5	19.23
Non-cardiovascular causes	Accidental / trauma	12	1	8.33
	Respiratory failure	12	2	16.67
	Malignancy	12	3	25.00
	Other	12	6	50.00

Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset :POLAND

	POLAND		
OUTCOME	**N**	**Events**	**%**
Stroke(not including systemic embolism)	2034	17	0.84
Primary Ischemic Stroke	2034	11	0.54
Primary intracerebral hemorrhage*	2034	2	0.10
Intracerebral	2034	1	0.05
Intraventricular	2034	1	0.05
Subdural Hematoma	2034	1	0.05
Undetermined	2034	4	0.20

***Note :Multiple choice question type that allows the respondent to choose one or multiple options from the list of possible answers.**

Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4 Full Analysis Dataset : POLAND

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	41	40.90	0	-	-
1	318	307.51	3	0.98	(0.32 to 3.03)
2	430	417.51	6	1.44	(0.65 to 3.20)
3	409	390.37	8	2.05	(1.03 to 4.10)
4+	824	773.53	37	4.78	(3.47 to 6.60)
Unknown	12	11.66	0	-	-

Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : POLAND

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	41	40.90	0	-	-
1	318	307.51	1	0.33	(0.05 to 2.31)
2	430	415.02	3	0.72	(0.23 to 2.24)
3	409	390.08	1	0.26	(0.04 to 1.82)
4+	824	771.40	12	1.56	(0.88 to 2.74)
Unknown	12	10.66	1	9.38	(1.32 to 66.57)

Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4 Full Analysis Dataset : POLAND

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	41	40.20	1	2.49	(0.35 to 17.66)
1	318	307.20	2	0.65	(0.16 to 2.60)
2	430	416.61	1	0.24	(0.03 to 1.70)
3	409	389.22	2	0.51	(0.13 to 2.06)
4+	824	772.78	3	0.39	(0.13 to 1.20)
Unknown	12	11.66	0	-	-